Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


09.09.2019

1 BJU Int
1 BMC Cancer
1 Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
2 Eur Urol
1 Int J Cancer
1 J Clin Oncol
4 J Nucl Med
1 J Surg Oncol
2 J Urol
3 Magn Reson Imaging
1 Oncogene
3 Prostate
1 Semin Oncol
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. ROBERTS MJ, Papa N, Perera M, Scott S, et al
    A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.
    BJU Int. 2019 Sep 5. doi: 10.1111/bju.14773.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Text format     Abstract available


    Cancer

  3. HIGANO CS, Armstrong AJ, Sartor AO, Vogelzang NJ, et al
    Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
    Cancer. 2019 Sep 4. doi: 10.1002/cncr.32445.
    PubMed     Text format     Abstract available


    Cancer Lett

  4. TSING T, Beretov J, Ni J, Bai X, et al
    Cancer stem cells in prostate cancer radioresistance.
    Cancer Lett. 2019 Sep 4. pii: S0304-3835(19)30457.
    PubMed     Text format     Abstract available


    Cancer Res

  5. GENG C, Rajapakshe K, Shah SS, Shou J, et al
    Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
    Cancer Res. 2019;79:4552.
    PubMed     Text format    


    Clin Cancer Res

  6. PONNUSAMY S, He Y, Hwang DJ, Thiyagarajan T, et al
    Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-1458.
    PubMed     Text format     Abstract available


    Eur Urol

  7. DONG L, Pienta KJ
    Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.
    Eur Urol. 2019 Aug 30. pii: S0302-2838(19)30678.
    PubMed     Text format    

  8. GORCHAKOV AA, Kulemzin SV, Kochneva GV, Taranin AV, et al
    Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Eur Urol. 2019 Aug 27. pii: S0302-2838(19)30658.
    PubMed     Text format     Abstract available


    Int J Cancer

  9. ZHANG S, Sugawara Y, Chen S, Beelman RB, et al
    Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study.
    Int J Cancer. 2019 Sep 4. doi: 10.1002/ijc.32591.
    PubMed     Text format     Abstract available


    J Clin Oncol

  10. PALLER CJ, Eisenberger MA
    Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm.
    J Clin Oncol. 2019 Sep 4:JCO1901863. doi: 10.1200/JCO.19.01863.
    PubMed     Text format    


    J Nucl Med

  11. ZACHO HD, Petersen LJ
    Reply LTE, Off-Target Report on (18)F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.234146. doi: 10.2967/jnumed.119.234146.
    PubMed     Text format    

  12. GHAFOOR S, Burger IA, Vargas HA
    Multimodality Imaging of Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.228320. doi: 10.2967/jnumed.119.228320.
    PubMed     Text format     Abstract available

  13. JANSEN BHE, Jansen RW, Wondergem M, Srbljin S, et al
    Lesion Detection and Interobserver Agreement with Advanced Image-Reconstructions for (18)F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.118.222513. doi: 10.2967/jnumed.118.222513.
    PubMed     Text format     Abstract available

  14. ZACHO HD, Fonager RF, Nielsen JB, Haarmark C, et al
    Observer agreement and accuracy of (18)F-sodium-fluoride PET/CT in the diagnosis of bone metastases in prostate cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.232686. doi: 10.2967/jnumed.119.232686.
    PubMed     Text format     Abstract available


    J Surg Oncol

  15. CAZZANIGA W, Godtman RA, Carlsson S, Ahlgren G, et al
    Population-based, nationwide registration of prostatectomies in Sweden.
    J Surg Oncol. 2019;120:803-812.
    PubMed     Text format     Abstract available


    J Urol

  16. VAN KALMTHOUT LWM, van Melick HHE, Lavalaye J, Meijer RP, et al
    Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
    J Urol. 2019 Sep 5:101097JU0000000000000531. doi: 10.1097/JU.0000000000000531.
    PubMed     Text format     Abstract available

  17. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Tian Z, et al
    Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.
    J Urol. 2019 Sep 4:101097JU0000000000000527. doi: 10.1097/JU.0000000000000527.
    PubMed     Text format     Abstract available


    Magn Reson Imaging

  18. MCNABB E, Wong R, Noseworthy MD
    Differentiating platinum coated brachytherapy seeds and gold fiducial markers with varying off-resonant frequency offsets.
    Magn Reson Imaging. 2019;60:68-75.
    PubMed     Text format     Abstract available

  19. BRUNESE L, Mercaldo F, Reginelli A, Santone A, et al
    Formal Methods for Prostate Cancer Gleason Score and Treatment Prediction using Radiomic Biomarkers.
    Magn Reson Imaging. 2019 Aug 30. pii: S0730-725X(19)30243.
    PubMed     Text format     Abstract available

  20. IKOMA Y, Kishimoto R, Tachibana Y, Omatsu T, et al
    Reference region extraction by clustering for the pharmacokinetic analysis of dynamic contrast-enhanced MRI in prostate cancer.
    Magn Reson Imaging. 2019 Sep 2. pii: S0730-725X(19)30209.
    PubMed     Text format     Abstract available


    Oncogene

  21. FENG T, Zhao R, Sun F, Lu Q, et al
    TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0991.
    PubMed     Text format     Abstract available


    Prostate

  22. JONCAS FH, Lucien F, Rouleau M, Morin F, et al
    Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23901.
    PubMed     Text format     Abstract available

  23. PERROUIN-VERBE MA, Schoentgen N, Talagas M, Garlantezec R, et al
    Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23904.
    PubMed     Text format     Abstract available

  24. JANG WS, Koh DH, Kim J, Lee JS, et al
    The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.
    Prostate. 2019 Sep 4. doi: 10.1002/pros.23905.
    PubMed     Text format     Abstract available


    Semin Oncol

  25. GRECO C, Vazirani AA, Pares O, Pimentel N, et al
    The evolving role of external beam radiotherapy in localized prostate cancer.
    Semin Oncol. 2019 Aug 22. pii: S0093-7754(19)30115.
    PubMed     Text format     Abstract available


    Urology

  26. JI C, Wang W, Lu Q, Fu Y, et al
    A new technique in fresh prostate cancer tissue biobanking based on MRI-transrectal ultrasound fusion biopsy.
    Urology. 2019 Sep 2. pii: S0090-4295(19)30751.
    PubMed     Text format     Abstract available

  27. ARABI A, Deebaja M, Yaguchi G, Pantelic M, et al
    Systematic biopsy does not contribute to disease upgrading in patients undergoing targeted biopsy for PI-RADS 5 lesions identified on magnetic resonance imaging in the course of active surveillance for prostate cancer.
    Urology. 2019 Aug 31. pii: S0090-4295(19)30789.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: